Last reviewed · How we verify
direct IV injection
This drug targets the PD-1 receptor to inhibit cancer cell growth.
This drug targets the PD-1 receptor to inhibit cancer cell growth. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.
At a glance
| Generic name | direct IV injection |
|---|---|
| Sponsor | Nantes University Hospital |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By binding to PD-1, the drug prevents cancer cells from evading the immune system, allowing the body's immune cells to attack and destroy the cancer cells. This leads to an anti-tumor response and potentially prolonged survival in patients with certain types of cancer.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
- Head and neck squamous cell carcinoma
Common side effects
- Pneumonitis
- Hypothyroidism
- Diarrhea
- Fatigue
- Nausea
Key clinical trials
- Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1) (PHASE1)
- Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan (PHASE2)
- Comparison Between Standard and Reduced Doses of Indocyanine Green in Fluorescence Cholangiography During Laparoscopic Cholecystectomy. (PHASE4)
- DB-3Q bmMSC-EVs in Patients With Perianal Fistulizing Crohn's Disease (PHASE2)
- A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (PHASE2)
- Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCL (PHASE2)
- Sodium Oxybate Versus Midazolam for Comfort Sedation (PHASE4)
- Study of 18FET PET in Functional Pituitary Adenomas With Indeterminate MRI Findings (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- direct IV injection CI brief — competitive landscape report
- direct IV injection updates RSS · CI watch RSS
- Nantes University Hospital portfolio CI